Literature DB >> 27852675

Serotype Distribution, Population Structure, and Antimicrobial Resistance of Group B Streptococcus Strains Recovered from Colonized Pregnant Women.

Sarah Teatero1, Patricia Ferrieri2, Irene Martin3, Walter Demczuk3, Allison McGeer4,5, Nahuel Fittipaldi6,5.   

Abstract

Using serotyping, multilocus sequence typing, and whole-genome sequencing (WGS) of selected strains, we studied the population structure of 102 group B Streptococcus (GBS) isolates prospectively sampled in 2014 from vaginal/rectal swabs of healthy pregnant women in metropolitan Toronto, Canada. We also determined the susceptibilities of each of the colonizing isolates to penicillin, erythromycin, clindamycin, tetracycline, and other antimicrobial agents. Overall, we observed a high rate of tetracycline resistance (89%) among colonizing GBS isolates. We found resistance to erythromycin in 36% of the strains, and 33% were constitutively or inducibly resistant to clindamycin. The most frequently identified serotypes were III (25%), Ia (23%), and V (19%). Serotype IV accounted for 6% of the colonizing isolates, a rate consistent with that observed among patients with invasive GBS infections in metropolitan Toronto. The majority of serotype IV isolates belonged to sequence type (ST)459, a tetracycline-, erythromycin-, and clindamycin-resistant ST first identified in Minnesota, which is considered to be the main driver of serotype IV GBS expansion in North America. WGS revealed that ST459 isolates from Canada are clonally related to colonizing and invasive ST459 organisms circulating in regions of the United States. We also used WGS to study recombination in selected colonizing strains from metropolitan Toronto, which revealed multiple episodes of capsular switching. Present and future circulating GBS organisms and their genetic diversity may influence GBS vaccine development.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  GBS vaccine; Streptococcus agalactiae; antibiotic resistance; colonizing GBS; group B Streptococcus; serotype IV; serotype switching

Mesh:

Substances:

Year:  2016        PMID: 27852675      PMCID: PMC5277510          DOI: 10.1128/JCM.01615-16

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  62 in total

1.  Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence.

Authors:  C E Rubens; M R Wessels; L M Heggen; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

2.  Identification of novel cps locus polymorphisms in nontypable group B Streptococcus.

Authors:  Srinivas V Ramaswamy; Patricia Ferrieri; Lawrence C Madoff; Aurea E Flores; Nikhil Kumar; Hervé Tettelin; Lawrence C Paoletti
Journal:  J Med Microbiol       Date:  2006-06       Impact factor: 2.472

3.  A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women.

Authors:  Geert Leroux-Roels; Cathy Maes; Julie Willekens; Fien De Boever; Richard de Rooij; Leah Martell; Lisa Bedell; Frederick Wittke; Karen Slobod; Peter Dull
Journal:  Vaccine       Date:  2016-03-05       Impact factor: 3.641

Review 4.  Group B Streptococcus surface proteins as major determinants for meningeal tropism.

Authors:  Asmaa Tazi; Samuel Bellais; Isabelle Tardieux; Shaynoor Dramsi; Patrick Trieu-Cuot; Claire Poyart
Journal:  Curr Opin Microbiol       Date:  2011-12-27       Impact factor: 7.934

5.  Molecular characterization of nontypeable group B streptococcus.

Authors:  Srinivas V Ramaswamy; Patricia Ferrieri; Aurea E Flores; Lawrence C Paoletti
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

6.  Identification of a high-virulence clone of type III Streptococcus agalactiae (group B Streptococcus) causing invasive neonatal disease.

Authors:  J M Musser; S J Mattingly; R Quentin; A Goudeau; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

7.  The surface protein HvgA mediates group B streptococcus hypervirulence and meningeal tropism in neonates.

Authors:  Asmaa Tazi; Olivier Disson; Samuel Bellais; Abdelouhab Bouaboud; Nicolas Dmytruk; Shaynoor Dramsi; Michel-Yves Mistou; Huot Khun; Charlotte Mechler; Isabelle Tardieux; Patrick Trieu-Cuot; Marc Lecuit; Claire Poyart
Journal:  J Exp Med       Date:  2010-10-18       Impact factor: 14.307

8.  Epidemiology of Invasive Group B Streptococcal Disease in Alberta, Canada, from 2003 to 2013.

Authors:  Areej Alhhazmi; Donna Hurteau; Gregory J Tyrrell
Journal:  J Clin Microbiol       Date:  2016-04-20       Impact factor: 5.948

Review 9.  The prevention of early-onset neonatal group B streptococcal disease.

Authors:  Deborah Money; Victoria M Allen
Journal:  J Obstet Gynaecol Can       Date:  2013-10

10.  Group B streptococcus serotype prevalence in reproductive-age women at a tertiary care military medical center relative to global serotype distribution.

Authors:  Danielle L Ippolito; Wesley A James; Deborah Tinnemore; Raywin R Huang; Mary J Dehart; Julie Williams; Mark A Wingerd; Samandra T Demons
Journal:  BMC Infect Dis       Date:  2010-11-24       Impact factor: 3.090

View more
  36 in total

1.  Diminished Capsule Exacerbates Virulence, Blood-Brain Barrier Penetration, Intracellular Persistence, and Antibiotic Evasion of Hyperhemolytic Group B Streptococci.

Authors:  Claire Gendrin; Sean Merillat; Jay Vornhagen; Michelle Coleman; Blair Armistead; Lisa Ngo; Anjali Aggarwal; Phoenicia Quach; Jacob Berrigan; Lakshmi Rajagopal
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 5.226

2.  A fatal case of pneumococcal sepsis years after splenectomy.

Authors:  Kevin J Solverson; Christopher J Doig
Journal:  CMAJ       Date:  2017-06-12       Impact factor: 8.262

3.  Vaginal co-colonization with multiple Group B Streptococcus serotypes.

Authors:  Ameneh Khatami; Tara M Randis; Larissa Tavares; Margaret Gegick; Evan Suzman; Adam J Ratner
Journal:  Vaccine       Date:  2018-12-08       Impact factor: 3.641

Review 4.  Perinatal Streptococcus agalactiae Epidemiology and Surveillance Targets.

Authors:  Lucy L Furfaro; Barbara J Chang; Matthew S Payne
Journal:  Clin Microbiol Rev       Date:  2018-08-15       Impact factor: 26.132

Review 5.  Streptococcus agalactiae in pregnant women in Brazil: prevalence, serotypes, and antibiotic resistance.

Authors:  Cilicia S do Nascimento; Nayara F B Dos Santos; Rita C C Ferreira; Carla R Taddei
Journal:  Braz J Microbiol       Date:  2019-08-20       Impact factor: 2.476

6.  Appropriate Antibiotic Use for Group B Streptococcus Prophylaxis Among Penicillin-Allergic Patients in Academic and Nonacademic Hospitals.

Authors:  Beth L Pineles; Katherine E Goodman; Lisa Pineles; Anthony D Harris
Journal:  Open Forum Infect Dis       Date:  2022-10-05       Impact factor: 4.423

7.  Significant shifts in the distribution of vaccine capsular polysaccharide types and rates of antimicrobial resistance of perinatal group B streptococci within the last decade in St. Petersburg, Russia.

Authors:  Elena Shipitsyna; Kira Shalepo; Svetlana Zatsiorskaya; Anna Krysanova; Maria Razinkova; Alexey Grigoriev; Alevtina Savicheva
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-03-24       Impact factor: 3.267

Review 8.  Control of Streptococcal Infections: Is a Common Vaccine Target Achievable Against Streptococcus agalactiae and Streptococcus pneumoniae.

Authors:  Edmund Bedeley; Andrea Gori; Dorothy Yeboah-Manu; Kanny Diallo
Journal:  Front Microbiol       Date:  2021-04-23       Impact factor: 5.640

9.  Identifying large-scale recombination and capsular switching events in Streptococcus agalactiae strains causing disease in adults in the UK between 2014 and 2015.

Authors:  Uzma Basit Khan; Elita Jauneikaite; Robert Andrews; Victoria J Chalker; Owen B Spiller
Journal:  Microb Genom       Date:  2022-03

Review 10.  Group B Streptococcal Maternal Colonization and Neonatal Disease: Molecular Mechanisms and Preventative Approaches.

Authors:  Kathryn A Patras; Victor Nizet
Journal:  Front Pediatr       Date:  2018-02-22       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.